Response to the H5N1 Global Outbreak
U.S. public health and clinical partners continue to monitor and respond to the global outbreak of highly pathogenic avian influenza A(H5N1). Thirteen human cases have been reported globally including one in the U.S., between January 2022 and June 1, 2023, of which six were hospitalized and two, tragically, died. Currently, A(H5N1) is believed to pose a low risk to the health of the general public, however we know that influenza viruses are unpredictable, and the situation can change rapidly.
Throughout the year, any samples testing influenza A positive from a multi-respiratory panel that did not return a valid subtype result should immediately be prioritized for shipment to a public health laboratory. Given the severity of some recent human infections with A(H5N1) viruses, CDC recommends increased surveillance among people who are severely ill with respiratory disease during summer months when seasonal influenza incidence is very low. During the summer months, CDC is asking that clinicians consider influenza testing for patients with respiratory illness, especially those with exposure to birds and/or swine. To identify potential novel influenza cases, hospitals and clinical laboratories are asked to subtype influenza A positive samples from ICU patients either in clinical laboratories or by sending them to state public health laboratories. As a reminder, human infection with any novel influenza A viruses is nationally notifiable and should be reported to state and local health departments.
Thank you for your continued support in this effort and the prevention and control of influenza. Please visit CDC H5N1 Bird Flu Summary or the IDPH Novel Influenza A-Z for the most up-to-date information.
|